The present invention provides a compound of formula I:
wherein R
1
, R
2
, R
3
, R
4
, and R
5
are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.
3-[2-(3-Amino-2-oxo-2H-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors
申请人:VERTEX PHARMACEUTICALS INCORPORATED
公开号:EP2412707A2
公开(公告)日:2012-02-01
The present invention provides a compound of formula I:
wherein R1, R2, R3, R4, and R5 are as defined herein. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.
本发明提供了一种式 I 的化合物:
其中 R1、R2、R3、R4 和 R5 如本文所定义。本发明还提供了治疗卡巴酶介导的疾病的药物组合物和使用这种组合物的方法,以及制备本发明化合物的工艺。
US7960415B2
申请人:——
公开号:US7960415B2
公开(公告)日:2011-06-14
[EN] CASPASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE CASPASE ET UTILISATIONS
申请人:VERTEX PHARMA
公开号:WO2004106304A2
公开(公告)日:2004-12-09
The present invention provides a compound of formula (I), wherein R1, R6C(O)-, HC(O)-, R6SO2-, R6OC(O)-, (R6)2NC(O)-, (R6) (H) NC (O)-, R6C (O) C (O) -, R6-, (R6) 2NC (O) C (O)-, R6 (H) NC (O) C (O)-, or R6OC (O) C (O)-; R2 is hydrogen, CF3, -halo, -OR7, -NO2, -OCF3, -CN, or R8; R3 is hydrogen or (C1-C4) -aliphatic-; R4 is -COOH or -COOR8; R5 is -CH2F or -CH2O-2, 3, 5, 6-tetrafluorophenyl. The present invention also provides pharmaceutical compositions and methods using such compositions for treating a caspase-mediated diseases and processes for preparing the compounds of the invention.
[EN] TREATMENT OF LIVER DISEASES WITH A CASPASE INHIBITOR<br/>[FR] TRAITEMENT DE MALADIES HÉPATIQUES AVEC UN INHIBITEUR DE CASPASE
申请人:VERTEX PHARMA
公开号:WO2010120880A1
公开(公告)日:2010-10-21
The present disclosure provides a method of using VX-166, a pan caspase inhibitor, for treating or reducing the symptoms of liver diseases, such as Non- Alcoholic Fatty Liver Disease (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and other diseases involving fibrosis, steatosis, or inflammation of the liver. The present disclosure also relates to methods for identifying agents useful for treating these diseases. The present disclosure also relates to additional therapeutics that can be used in combination with VX-166 for the treatment of these diseases.